The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
Open accessAbstract
Significance: Cancer immune evasion is well described. In some cases, this may be overcome by enhancing T-cell responses. We show that despite the presence of antitumor T cells, immunotherapeutic antibodies are ineffective in a murine pancreatic cancer model recapitulating the human disease. Removing the carcinoma-associated fibroblast (CAF) expressing fibroblast activation protein (FAP) from tumors permitted immune control of tumor growth and uncovered the efficacy of these immunotherapeutic antibodies. FAP + CAFs are the only tumoral source of chemokine (C-X-C motif) ligand 12 (CXCL12), and administering AMD3100, an inhibitor of chemokine (C-X-C motif) receptor 4, a CXCL12 receptor, also revealed the antitumor effects of an immunotherapeutic antibody and greatly diminished cancer cells. These findings may have wide clinical relevance because FAP + cells are found in almost all human adenocarcinomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“targeting CXCL12 signalling could be considered to be targeting CAFs as they are the major source of the chemokine in many tumours121.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [121]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“most studies have suggested an immunosuppressive role of CAFs121”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [121]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Interference with the action of CXCL12 produced by CAFs promotes T cell-mediated tumour control16,121,122”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [121]
In the citing paper
“the transcriptional profiles of apCAFs overlap with mesothelial cells150, and based on lineage tracing studies in mice have been postulated to derive from a mesothelial origin145”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [150]
In the citing paper
“They can further differentiate into myofibroblasts that express α-smooth muscle actin232.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [232]
In the citing paper
“fibroblast activation protein (FAP)+ CAFs inhibited anti-tumor function of T cells in gastric cancer and pancreatic cancer and targeting these FAP+ subtypes enhanced tumor response to ICB (Feig et al., 2013).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Feig et al., 2013
In the citing paper
“Moreover, CAF depletion using diphtheria toxin‐based immunotherapy reduced cancer growth by increasing CD8+ Teff‐cell infiltration to the TME [102].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [102]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,427
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Cited by
Sorted by citations
Items 301–400 of 1,000
Targeting Cancer Associated Fibroblasts in Liver Fibrosis and Liver Cancer Using Nanocarriers
Kaps, L., & Schuppan, D. (2020) · Cells · doi:10.3390/cells9092027 · Cited by 160
Utilizing chemokines in cancer immunotherapy
Märkl, F., Huynh, D., Endres, S., & Kobold, S. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.04.001 · Cited by 157
Stromal cues regulate the pancreatic cancer epigenome and metabolome
Sherman, M. H., Yu, R. T., Tseng, T. W., Sousa, C. M., Liu, S., Truitt, M. L., He, N., Ding, N., Liddle, C., Atkins, A. R., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620164114 · Cited by 147
Zhan, H., Zhou, B., Cheng, Y., Xu, J., Wang, L., Zhang, G., & Hu, S. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.041 · Cited by 155
Carcinogenesis of Pancreatic Ductal Adenocarcinoma
Störz, P., & Crawford, H. C. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.02.059 · Cited by 154
CXCR4 Ligands: The Next Big Hit?
Walenkamp, A., Lapa, C., Herrmann, K., & Wester, H. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.186874 · Cited by 156
Elahi-Gedwillo, K. Y., Carlson, M., Zettervall, J., & Provenzano, P. P. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1334 · Cited by 158
Ma, Y., Li, J., Wang, H., Chiu, Y., Kingsley, C. V., Fry, D., Delaney, S. N., Wei, S. C., Zhang, J., Maitra, A., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.03.018 · Cited by 154
Duperret, E. K., Trautz, A., Ammons, D. T., Perales‐Puchalt, A., Wise, M. C., Yan, J., Reed, C., & Weiner, D. B. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2033 · Cited by 158
Immunotherapy for pancreatic cancer: Barriers and breakthroughs
Torphy, R. J., Zhu, Y., & Schulick, R. D. (2018) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12176 · Cited by 154
Garg, B., Giri, B., Modi, S., Sethi, V., Castro, I., Umland, O., Ban, Y. J., Lavania, S., Dawra, R. K., Banerjee, S., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.05.051 · Cited by 152
Opzoomer, J. W., Sosnowska, D., Anstee, J. E., Spicer, J. F., & Arnold, J. N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01654 · Cited by 155
The spatio-temporal control of effector T cell migration
Fowell, D. J., & Kim, M. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00507-0 · Cited by 154
Cancer-Associated Fibroblasts and Tumor-Associated Macrophages in Cancer and Cancer Immunotherapy
Raskov, H., Orhan, A., Gaggar, S., & Gögenur, I. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.668731 · Cited by 150
Denton, A. E., Roberts, E. W., Linterman, M. A., & Fearon, D. T. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412910111 · Cited by 150
Self-citationLiu, H., Shen, J., & Lü, K. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.02.128 · Cited by 150
Peng, S.-B., Zhang, X., Paul, D. C., Kays, L. M., Gough, W. H., Stewart, J. A., Uhlik, M. T., Chen, Q., Hui, Y., Zamek‐Gliszczynski, M. J., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0850 · Cited by 150
Bougherara, H., Mansuet‐Lupo, A., Alifano, M., Ngô, C., Damotte, D., Frère‐Belda, M. L., Donnadieu, E., & Peranzoni, E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00500 · Cited by 156
Exploring the Tumor Microenvironment with Nanoparticles
Miao, L., & Huang, L. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-16555-4_9 · Cited by 155
Cancer-Associated Fibroblasts: Understanding Their Heterogeneity
Louault, K., Li, R., & DeClerck, Y. A. (2020) · Cancers · doi:10.3390/cancers12113108 · Cited by 162
Cytokine and Chemokine Signals of T‐Cell Exclusion in Tumors
Zhang, Y., Guan, X.-Y., & Jiang, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594609 · Cited by 133
Stromal dynamic reciprocity in cancer: intricacies of fibroblastic-ECM interactions
Alexander, J. I., & Cukierman, E. (2016) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2016.05.002 · Cited by 149
Current and Emerging Therapies in Metastatic Pancreatic Cancer
Manji, G. A., Olive, K. P., Saenger, Y. M., & Oberstein, P. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2319 · Cited by 145
Twist1 Is a Key Regulator of Cancer-Associated Fibroblasts
Lee, K.-W., Yeo, S.-Y., Sung, C. O., & Kim, S. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0350 · Cited by 145
Cancer-associated fibroblasts: how do they contribute to metastasis?
Kwa, M. Q., Herum, K. M., & Brakebusch, C. (2019) · Clinical & Experimental Metastasis · doi:10.1007/s10585-019-09959-0 · Cited by 150
Monteran, L., Ershaid, N., Doron, H., Zait, Y., Scharff, Y., Ben-Yosef, S., Avivi, C., Barshack, I., Sonnenblick, A., & Erez, N. (2022) · Nature Communications · doi:10.1038/s41467-022-33598-x · Cited by 150
Xue, M., Zhu, Y., Jiang, Y., Han, L., Shi, M., Su, R. J., Wang, L., Xiong, C., Wang, C., Wang, T., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40314-w · Cited by 153
Pernas, S., Martín, M., Kaufman, P. A., Gil-Martín, M., Pardo, P. G., López‐Tarruella, S., Manso, L., Ciruelos, E. M., Fidalgo, J. A. P., Hernándo, C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30147-5 · Cited by 143
Preclinical murine tumor models: A structural and functional perspective
Guérin, M. V., Finisguerra, V., den Eynde, B. J. V., Bercovici, N., & Trautmann, A. (2020) · eLife · doi:10.7554/elife.50740 · Cited by 160
Engineering-enhanced CAR T cells for improved cancer therapy
Milone, M. C., Xu, J., Chen, S., Collins, M. A., Zhou, J., Powell, D. J., & Melenhorst, J. J. (2021) · Nature Cancer · doi:10.1038/s43018-021-00241-5 · Cited by 148
Lai, B. F. L., Lu, R. X. Z., Hu, Y., Davenport Huyer, L., Dou, W., Wang, E. Y., Radulovich, N., Tsao, M. S., Sun, Y., & Radisic, M. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202000545 · Cited by 142
Perspectives in the treatment of pancreatic adenocarcinoma
Arregui, A. C. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i31.9297 · Cited by 146
Tabdanov, E. D., Rodríguez-Merced, N. J., Cartagena‐Rivera, A. X., Puram, V. V., Callaway, M. K., Ensminger, E. A., Pomeroy, E. J., Yamamoto, K., Lahr, W. S., Webber, B. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22985-5 · Cited by 145
Yamamoto, Y., Kasashima, H., Fukui, Y., Tsujio, G., Yashiro, M., & Maeda, K. (2022) · Cancer Science · doi:10.1111/cas.15609 · Cited by 138
Koncina, E., Nurmik, M., Pozdeev, V. I., Gilson, C., Tsenkova, M., Begaj, R., Stang, S., Gaigneaux, A., Weindorfer, C., Rodriguez, F., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39953-w · Cited by 147
Fu, Y., Liu, S., Zeng, S., & Shen, H. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0815-z · Cited by 137
Shen, L., Li, J., Liu, Q., Song, W., Zhang, X., Tiruthani, K., Hu, H., Das, M., Goodwin, T. J., Liu, R., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b00967 · Cited by 139
Xiang, Z., Li, J., Song, S., Wang, J., Cai, W., Hu, W., Ji, J., Zhu, Z., Zang, L., Yan, R., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1318-5 · Cited by 138
Beyond Cell Motility: The Expanding Roles of Chemokines and Their Receptors in Malignancy
Morein, D., Erlichman, N., & Ben‐Baruch, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00952 · Cited by 138
Hossain, M. A., Liu, G., Dai, B., Si, Y., Yang, Q., Wazir, J., Birnbaumer, L., & Yang, Y. (2020) · Medicinal Research Reviews · doi:10.1002/med.21727 · Cited by 141
Cancer-associated fibroblasts: The chief architect in the tumor microenvironment
Sarkar, M., Nguyen, T., Gundre, E., Ogunlusi, O., El-Sobky, M. H., Giri, B., & Sarkar, T. R. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1089068 · Cited by 150
Enfield, K. S. S., Colliver, E., Lee, C., Magness, A., Moore, D. A., Sivakumar, M., Grigoriadis, K., Pich, O., Karasaki, T., Hobson, P. S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1380 · Cited by 151
The biological underpinnings of therapeutic resistance in pancreatic cancerPreprint
Beatty, G. L., Werba, G., Lyssiotis, C. A., & Simeone, D. M. (2021) · Genes & Development · doi:10.1101/gad.348523.121 · Cited by 139
Role of immune cells in pancreatic cancer from bench to clinical application
Chang, J. H., Jiang, Y., & Pillarisetty, V. G. (2016) · Medicine · doi:10.1097/md.0000000000005541 · Cited by 137
Infiltration of CD8 + T cells into tumor cell clusters in triple-negative breast cancer
Li, X., Gruosso, T., Zuo, D., Ömeroğlu, A., Meterissian, S. H., Guiot, M., Salazar, A., Park, M., & Levine, H. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817652116 · Cited by 132
Mesenchymal stem cells: From regeneration to cancer
Li, P., Gong, Z., Shultz, L. D., & Ren, G. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.005 · Cited by 133
Wang, X., Li, X., Wei, X., Jiang, H., Lan, C., Yang, S., Wang, H., Yang, Y., Tian, C., Xu, Z., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0144-8 · Cited by 137
Mouse Tumor Models for Advanced Cancer Immunotherapy
Chulpanova, D. S., Kitaeva, K. V., Rutland, C. S., Rizvanov, A. A., & Solovyeva, V. V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114118 · Cited by 138
GEMMs as preclinical models for testing pancreatic cancer therapies
Gopinathan, A., Morton, J. P., Jodrell, D. I., & Sansom, O. J. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.021055 · Cited by 141
Self-citationCXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent
Wang, J., Tannous, B. A., Poznansky, M. C., & Chen, H. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105010 · Cited by 138
CAR T cell therapy in solid tumors: A review of current clinical trials
Patel, U., Abernathy, J., Savani, B. N., Oluwole, O. O., Sengsayadeth, S. M., & Dholaria, B. (2021) · eJHaem · doi:10.1002/jha2.356 · Cited by 133
Wang, H., Liang, Y., Liu, Z., Zhang, R., Chao, J., Wang, M., Liu, M., Qiao, L., Xuan, Z., Zhao, H., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008721 · Cited by 150
Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities
Xia, A., Wang, X., Lu, Y., Lu, X., & Sun, B. (2017) · Oncotarget · doi:10.18632/oncotarget.19361 · Cited by 132
Liu, X., Jiang, J., Liao, Y., Tang, I., Zheng, E., Qiu, W., Lin, M. J., Wang, X., Ji, Y. C., Mei, K., et al. (2021) · Advanced Science · doi:10.1002/advs.202002147 · Cited by 129
Beatty, G. L., & O’Hara, M. H. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.06.010 · Cited by 131
Jia, D., Liu, Z., Deng, N., Tan, T. Z., Huang, R. Y., Taylor‐Harding, B., Cheon, D., Lawrenson, K., Wiedemeyer, W. R., Walts, A. E., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.09.001 · Cited by 129
Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer
Miao, L., Li, J., Liu, Q., Feng, R., Das, M., Lin, C. M., Goodwin, T. J., Dorosheva, O., Liu, R., & Huang, L. (2017) · ACS Nano · doi:10.1021/acsnano.7b01786 · Cited by 132
Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion
Jiang, H., Liu, X., Knolhoff, B. L., Hegde, S., Lee, K. B., Jiang, H., Fields, R. C., Pachter, J. A., Lim, K.-H., & DeNardo, D. G. (2020) · Gut · doi:10.1136/gutjnl-2018-317424 · Cited by 130
CAFs orchestrates tumor immune microenvironment—A new target in cancer therapy?
Zhang, C., Fei, Y., Wang, H., Hu, S., Liu, C., Hu, R., & Du, Q. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1113378 · Cited by 132
Zhao, J., Wang, H., Hsiao, C.-H., Chow, D. S., Koay, E. J., Kang, Y., Wen, X., Huang, Q., Ma, Y., Bankson, J. A., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.01.014 · Cited by 128
Darragh, L. B., Oweida, A., & Karam, S. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03154 · Cited by 133
Efficiency of CAR-T Therapy for Treatment of Solid Tumor in Clinical Trials: A Meta-Analysis
Hou, B., Tang, Y., Li, W., Zeng, Q., & Chang, D. (2019) · Disease Markers · doi:10.1155/2019/3425291 · Cited by 131
FAPI PET/CT: Will It End the Hegemony of 18F-FDG in Oncology?
Hicks, R. J., Roselt, P. D., Kallur, K. G., Tothill, R. W., & Mileshkin, L. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.256271 · Cited by 131
Cancer-Associated Fibroblasts: Versatile Players in the Tumor Microenvironment
Ganguly, D., Chandra, R., Karalis, J. D., Teke, M. E., Aguilera, T. A., Maddipati, R., Wachsmann, M., Ghersi, D., Siravegna, G., Zeh, H. J., et al. (2020) · Cancers · doi:10.3390/cancers12092652 · Cited by 130
Harnessing the chemokine system to home CAR-T cells into solid tumors
Foeng, J., Comerford, I., & McColl, S. R. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100543 · Cited by 133
Wong, H. Y., Sheng, Q., Hesterberg, A. B., Croessmann, S., Rios, B. L., Giri, K. R., Jackson, J., Miranda, A. X., Watkins, E., Schaffer, K. R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33780-1 · Cited by 131
The roles of tumor- and metastasis-promoting carcinoma-associated fibroblasts in human carcinomas
Mezawa, Y., & Orimo, A. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2471-1 · Cited by 127
Recent insights into the biology of pancreatic cancer
Yao, W., Maitra, A., & Ying, H. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102655 · Cited by 127
Norton, J. A., Foster, D. S., Chinta, M. S., Titan, A. L., & Longaker, M. T. (2020) · Cancers · doi:10.3390/cancers12051347 · Cited by 130
T cell egress via lymphatic vessels is tuned by antigen encounter and limits tumor control
Steele, M. M., Jaiswal, A., Delclaux, I., Dryg, I. D., Murugan, D., Femel, J., Son, S., du Bois, H., Hill, C. M., Leachman, S. A., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01443-y · Cited by 130
From gatekeepers to providers: regulation of immune functions by cancer-associated fibroblasts
Arpinati, L., & Scherz‐Shouval, R. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.01.007 · Cited by 129
Wehrli, M., Guinn, S. R., Birocchi, F., Kuo, A., Sun, Y., Larson, R. C., Almazan, A. J., Scarfò, I., Bouffard, A. A., Bailey, S. R., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3841 · Cited by 134
Zhao, F., Evans, K., Xiao, C., DeVito, N., Theivanthiran, B., Holtzhausen, A., Siska, P. J., Blobe, G. C., & Hanks, B. A. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0086 · Cited by 117
“andanti–CTLA-4 in this tumormodel (20).”
Liu, Y., Sun, Y., Wang, P., Li, S., Dong, Y., Zhou, M., Shi, B., Jiang, H., Sun, R., & Li, Z. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04080-z · Cited by 128
Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
Hilmi, M., Bartholin, L., & Neuzillet, C. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i20.2137 · Cited by 126
Mathew, E., Brannon, A., Vecchio, A. D., Garcia, P. E., Penny, M. K., Kane, K. T., Vinta, A., Buckanovich, R. J., & di Magliano, M. P. (2016) · Neoplasia · doi:10.1016/j.neo.2016.01.005 · Cited by 122
Ferdinandus, J., Costa, P. F., Kessler, L., Weber, M., Hirmas, N., Kostbade, K., Bauer, S., Schuler, M., Ahrens, M., Schildhaus, H., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262468 · Cited by 148
Chemotherapy and tumor microenvironment of pancreatic cancer
Liu, Q., Liao, Q., & Zhao, Y. (2017) · Cancer Cell International · doi:10.1186/s12935-017-0437-3 · Cited by 120
Stromal reengineering to treat pancreas cancer
Stromnes, I. M., DelGiorno, K. E., Greenberg, P. D., & Hingorani, S. R. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu115 · Cited by 119
Cannon, A. C., Thompson, C. M., Hall, B. R., Jain, M., Sushil Kumar, K., & Batra, S. K. (2018) · Genes & Cancer · doi:10.18632/genesandcancer.171 · Cited by 120
Ferrara, B., Pignatelli, C., Cossutta, M., Citro, A., Courty, J., & Piemonti, L. (2021) · Cancers · doi:10.3390/cancers13174442 · Cited by 134
Xiang, X., Niu, Y., Wang, Z.-H., Ye, L., Peng, W., & Zhou, Q. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.07.006 · Cited by 123
Belle, J. I., Sen, D., Baer, J. M., Liu, X., Lander, V. E., Ye, J., Sells, B. E., Knolhoff, B. L., Ahmad, F. F., Kang, L., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0428 · Cited by 124
Differential contribution of pancreatic fibroblast subsets to the pancreatic cancer stroma
Garcia, P. E., Adoumie, M., Kim, E. C., Zhang, Y., Scales, M. K., El-Tawil, Y. S., Shaikh, A. Z., Wen, H.-J., Bednar, F., Allen, B. L., et al. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.05.004 · Cited by 110
Hu, S., Lu, H., Xie, W., Wang, D., Shan, Z., Xing, X., Wang, X.-M., Fang, J., Dong, W., Dai, W., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci157649 · Cited by 129
Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors
Kosti, P., Maher, J. F., & Arnold, J. N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01104 · Cited by 118
Loenhout, J. V., Flieswasser, T., Boullosa, L. F., Waele, J. D., Audenaerde, J. R. M. V., Marcq, E., Jacobs, J., Lin, A. G., Lion, E., Dewitte, H., et al. (2019) · Cancers · doi:10.3390/cancers11101597 · Cited by 122
Broz, M. T., Ko, E. Y., Ishaya, K., Xiao, J.-F., Simone, M. C. D., Hoi, X. P., Piras, R., Gala, B., Tessaro, F. H. G., Karlstaedt, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46504-4 · Cited by 123
Wei, L., Ye, H., Li, G., Lu, Y., Zhou, Q., Zheng, S., Lin, Q., Liu, Y., Li, Z., & Chen, R. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03420-5 · Cited by 118
Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions
Brunner, M., Wu, Z., Krautz, C., Pilarsky, C. P., Grützmann, R., & Weber, G. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184543 · Cited by 121
B cell–Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer
Mirlekar, B., Michaud, D. E., Lee, S. J., Kren, N. P., Harris, C., Greene, K. G., Goldman, E. C., Gupta, G. P., Fields, R. C., Hawkins, W. G., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0349 · Cited by 122
Cancer-associated fibroblasts: key determinants of tumor immunity and immunotherapy
Barrett, R., & Puré, E. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.03.004 · Cited by 119
Lander, V. E., Belle, J. I., Kingston, N. L., Herndon, J. M., Hogg, G. D., Liu, X., Kang, L.-I., Knolhoff, B. L., Bogner, S. J., Baer, J. M., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0192 · Cited by 114
3D approaches to model the tumor microenvironment of pancreatic cancer
Bort, E. T., Kieler, M., Sharma, S., Candido, J. B., & Loessner, D. (2020) · Theranostics · doi:10.7150/thno.42441 · Cited by 122
Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer
Rech, A. J., Dada, H., Kotzin, J. J., Henao‐Mejia, J., Minn, A. J., Victor, C. T.-S., & Vonderheide, R. H. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3821 · Cited by 117
Epithelial and stromal co-evolution and complicity in pancreatic cancer
Hingorani, S. R. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00530-w · Cited by 108
The influence of microenvironment on tumor immunotherapy
Zhang, J., Shi, Z., Xu, X., Yu, Z., & Mi, J. (2019) · FEBS Journal · doi:10.1111/febs.15028 · Cited by 112
Maddalena, M., Mallel, G., Nataraj, N. B., Shreberk‐Shaked, M., Hassin, O., Mukherjee, S., Arandkar, S., Rotkopf, R., Kapsack, A., Lambiase, G., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025631118 · Cited by 124
Spatial mapping of transcriptomic plasticity in metastatic pancreatic cancer
Pei, G., Min, J., Rajapakshe, K., Branchi, V., Liu, Y., Selvanesan, B. C., Thege, F. I., Sadeghian, D., Zhang, D., Cho, K. S., et al. (2025) · Nature · doi:10.1038/s41586-025-08927-x · Cited by 121
Masugi, Y., Abe, T., Ueno, A., Fujii‐Nishimura, Y., Ojima, H., Endo, Y., Fujita, Y., Kitago, M., Shinoda, M., Kitagawa, Y., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0291-z · Cited by 113
Metadata
- Authors
- Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., Teichmann, S. A., Janowitz, T., Jodrell, D. I., Tuveson, D. A., & Fearon, D. T.
- Affiliations
- University of Cambridge (GB)
- MRC Laboratory of Molecular Biology (GB)
- Johns Hopkins University (US)
- Ludwig Collaborative Laboratory, Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21231; and
- European Bioinformatics Institute (GB)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2013-11-25
- Volume
- 110
- Issue
- 50
- Pages
- 20212-20217
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3864274
- OpenAlex
- W2086834665
- Cited by
- 2,100
- References
- 28
- Citations by year
- 2026: 252 · 2025: 157 · 2024: 226 · 2023: 214 · 2022: 221 · 2021: 244 · 2020: 203 · 2019: 149 · 2018: 125 · 2017: 119 · 2016: 95 · 2015: 63 · 2014: 30
- FWCI
- 33.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Funders
- Wellcome Trust
- Cancer Research UK (15678)
- National Institute for Health and Care Research (CL-2011-14-007)
- Medical Research Council (MC_PC_12012)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Keywords
- pancreatic ductal adenocarcinoma, CXCL12, fibroblast activation protein, cancer-associated fibroblasts, PD-L1 blockade, CTLA-4 blockade, tumor immune evasion, tumor stroma, CXCR4 inhibition, AMD3100, CD8+ T cells, chemokine signaling, immunotherapy resistance
- MeSH terms
- Cyclams, Fibroblast Activation Protein Alpha, Analysis of Variance, Animals, Base Sequence, Benzylamines, Fibroblasts, Flow Cytometry, Fluorescent Antibody Technique, Heterocyclic Compounds, Immunohistochemistry, Immunotherapy, Membrane Proteins, Molecular Sequence Data, Pancreatic Neoplasms, Endopeptidases, Serine Endopeptidases, Sequence Analysis, RNA, Gelatinases, Tumor Escape, Carcinoma, Pancreatic Ductal, Mice, Chemokine CXCL12, Enzyme-Linked Immunospot Assay
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
